Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Teva

With rising healthcare expenditure, growing need for precision medicine, innovations in biologics and gene editing, and rapid adoption of advanced technologies, the pharma industry is well-poised for significant growth and expansion. Thus, quality pharma stocks Wave Life (WVE), Teva Pharmaceuticals (TEVA), and Collegium (COLL) could be smart buys for substantial…

StockNews.com

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

StockNews.com

Prescribe to Profits With These 3 Pharma Stocks

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

StockNews.com

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

StockNews.com

Teva to pay $225M to settle cholesterol drug price-fixing charges

The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing charges related to sales of a widely used cholesterol-lowering drug

The Independent UK

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals (TEVA) are set to reap the rewards. However, which of the two is the better value stock for August? Read more to find…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

The ES Shopping Shortlist: What to shop, see and know in June 2023

These are the hot-off-the-press launches to know

Evening Standard

Best festival outfits of 2023 from crochet to sequins

Going all out is the aim of the game

Evening Standard

Best sandals for men to get set for the summer months

Start the season with the right foot forward

Evening Standard

3 Stocks with More Upside Potential

Coupled with macroeconomic headwinds, the sudden regional banking failures have marred investor sentiments. Moreover, amid anticipations of a recession, the existing market volatilities are not likely to subside anytime soon. Given this backdrop, we think the strong growth prospects of Gilead Sciences (GILD), Teva Pharmaceutical (TEVA), and MacroGenics (MGNX) make…

StockNews.com

Chicago is seeing an increase in fatal meth overdoses. Here’s why.

110 people in Chicago died from methamphetamine overdoses in 2021, a steep rise from 47 in 2019. The fatal overdoses are linked to a rise in demand, increased supply and deadlier “cocktails” as dealers cut the drug with fentanyl and cocaine.

Chicago Sun-Times

4 Pharma Stocks You Shouldn’t Think Twice About Buying in 2023

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

StockNews.com

‘It’s fun, it’s versatile, it’s functional’: terry towelling’s time in the sun

Emerging designers are putting a sustainable twist on the quintessentially 70s fabric, that’s practical at the beach and playful off it

The Guardian - AU

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Stocks to Buy Before the Next Big Bull Rally

Cooling inflationary pressures and the Fed’s indication of a slower pace of rate hikes ahead could generate a potential bull rally this month. So, we believe investors should load up on fundamentally strong stocks General Motors Company (GM), BorgWarner Inc. (BWA), Teva Pharmaceutical Industries Limited (TEVA), and Rambus Inc. (RMBS).…

StockNews.com

4 Stocks to Amplify Your Portfolio in Q4

With investors regaining confidence in the markets amid cooling down inflation, fundamentally strong stocks CSX Corporation (CSX), Teva Pharmaceutical Industries (TEVA), Celestica Inc. (CLS), and DLH Holdings (DLHC) may be ideal investments to capitalize on their potential rebound. Continue reading….

Benzinga

Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11

Bloomberg

StockNews.com

4 Health Care Stocks That Could Keep Your Portfolio From Needing a Check-Up

The healthcare industry tends to withstand macroeconomic pressure better than other industries due to the almost inelastic demand for medical products and services. With a recession expected next year, investors could look to capitalize on the defensive characteristics and long-term prospects of the industry by investing in quality medical stocks…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

New York could get $524M under opioid settlements with Teva

New York Attorney General Letitia James says the state will receive up to $524 million from drugmaker Teva to settle claims that the company contributed to the U.S. opioid epidemic

StockNews.com

Buy These 2 Growth Stocks Before They Boom

The red-hot inflation and the Fed’s hawkish stance are raising the possibility of a recession. However, historical trends suggest that the market could experience a rebound later this month or early next month. So, we think it could be wise to invest in growth stocks Teva Pharmaceutical (TEVA) and Forrester…

Reason

Blame the Government for the Adderall Shortage

Limiting the supply of a controlled substance does not remove demand. Users simply look elsewhere, including more unsavory sources.

The Guardian - US

US shortage of Adderall is due to increased demand, FDA and drug-makers say

FDA says supply does not meet demand and drug-maker says backorders are due to ‘significant rise’ in prescription rates

Los Angeles Times

Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

1 Stock Warren Buffett Might Have Sold Too Soon

Warren Buffett’s diversified holding company Berkshire Hathaway exited its position in drugmaker TEVA by the end of 2021 at a loss of approximately $365 million on its four-year-long bet. However, Buffett appears to have exited to stock too soon as TEVA witnessed a significant reversal this year, gaining 34.5% year-to-date.…

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.